Hutchmed (China) Limited (HCM) ORD USD0.10
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Hutchmed to receive $20m Fruzaqla milestone payment
31 October 2024 11:04
(Sharecast News) - Hutchmed China announced on Thursday that it was set to receive a $20m milestone payment from its partner Takeda, after sales of 'Fruzaqla', or fruquintinib, surpassed $200m.
-
Hutchmed reports positive results from AstraZeneca lung cancer collaboration
16 October 2024 11:41
(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys',...
-
Hutchmed partner Takeda gets Japanese approval for Fruzaqla
24 September 2024 11:06
(Sharecast News) - Hutchmed China announced on Tuesday that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market...
-
Hutchmed to present new and updated clinical trial data
9 September 2024 12:31
(Sharecast News) - Hutchmed China has announced that it would present new and updated clinical trial data at two major oncology conferences - the 2024 World Conference on Lung Cancer (WCLC24) in San Diego,...
-
Hutchmed withdraws supplemental new drug application in China
30 August 2024 10:53
(Sharecast News) - Hutchmed China has voluntarily withdrawn its supplemental new drug application (NDA) in China for the use of fruquintinib in combination with paclitaxel for second-line treatment of...
-
Oncology revenue drives first-half growth for Hutchmed
31 July 2024 12:16
(Sharecast News) - Hutchmed China reported a robust set of first-half financial results on Wednesday, underpinned by significant growth in oncology product revenue and a solid cash position to support...
-
Hutchmed gets tazemetostat new drug application approved in China
4 July 2024 14:03
(Sharecast News) - Hutchmed China announced on Thursday that the China National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for tazemetostat, granting it priority...
-
Hutchmed partner gets European approval for fruqintinib
24 June 2024 12:20
(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients...
-
Hutchmed publishes positive sovleplenib trial results
17 June 2024 09:28
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
-
Hutchmed China launches two cancer treatment trials
14 May 2024 11:42
(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment.
-
Hutchmed China to make several presentations at cancer research meeting
5 April 2024 11:54
(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer...
-
Hutchmed endometrial cancer treatment gets priority review in China
2 April 2024 12:11
(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and...
Company announcements Announcements
-
FRUZAQLA® Launched in Japan by Takeda
22 November 2024 07:00
HUTCHMED (China) Limited
-
Appointment of Independent Non-executive Director
20 November 2024 09:30
HUTCHMED (China) Limited
-
Total Voting Rights
31 October 2024 08:30
HUTCHMED (China) Limited
-
Vesting of awards under the LTIP
21 October 2024 09:30
HUTCHMED (China) Limited
-
SAVANNAH: clinically meaningful response rate
16 October 2024 07:00
HUTCHMED (China) Limited
-
Japan Approval for FRUZAQLA
24 September 2024 08:00
HUTCHMED (China) Limited
-
Total Voting Rights
30 August 2024 09:30
HUTCHMED (China) Limited
-
Update on Fruquintinib for Gastric Cancer in China
30 August 2024 07:00
HUTCHMED (China) Limited
-
Standard form for notification of major holdings
22 August 2024 09:30
HUTCHMED (China) Limited
-
LTIP and Share Option Scheme
6 August 2024 10:00
HUTCHMED (China) Limited
-
2024 Interim Results and Business Updates
31 July 2024 12:00
HUTCHMED (China) Limited
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.